Abstract
Parasites and parasite-derived molecules play a complex role in cancer biology, and growing evidence suggests they influence cancer development. This systematic review explores the mechanisms underlying the pro-tumour and anti-tumour effects of parasites and their molecules in experimental cancer models. A total of 34 studies were reviewed, covering whole parasites and parasite-derived molecules, including vesicles, peptides, proteins, and miRNAs, across different cancer types. The evidence shows that the effects of parasites and parasite-derived molecules on cancer depend strongly on the parasite species, the molecules involved, and the host response. Pro-tumour effects were mainly associated with chronic inflammation, oxidative stress, epithelial proliferation, and immune modulation. In contrast, anti-tumour effects were associated with direct cytotoxicity, inhibition of migration, and immune activation. Several parasite-derived molecules exhibited anti-tumour effects beyond their usual sites of infection, suggesting broader biological activity and potential therapeutic relevance. In conclusion, this review highlights the dual, context-dependent influence of parasites and parasite-derived molecules on cancer progression and supports further mechanistic and translational studies to investigate their potential as cancer-promoting factors and anticancer therapeutic candidates.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420250656117.
Introduction
Cancer continues to be the primary cause of mortality globally (). Cancer arises through the accumulation of genetic and metabolic alterations that disrupt cellular pathways controlling proliferation, apoptosis, DNA repair, and immune surveillance (). The cause of cancer involves a complex interplay between endogenous factors like mutations, hormonal influences, and metabolic disturbances, and exogenous factors such as environmental carcinogens, chronic inflammation, and infectious diseases (, ). Around 2.2 million new cancer cases globally are associated with viral and bacterial infections (). Meanwhile, human parasitic infections are less appreciated (). Infections can contribute to cancer development through various mechanisms, including chronic inflammation, pathogen-encoded oncoproteins that induce genomic alterations, and immunosuppression that diminishes tumour surveillance ().
Parasites have been extensively studied to understand their relationship with their hosts. They remain prevalent in many endemic settings and are linked to cancer development (). Parasites can promote cancer through chronic infections that trigger chronic inflammation, tissue damage, fibrosis, and immune dysregulation. One of their strategies for sustained presence with the host is to evade immune detection by secreting molecules that suppress the immune response (). In this context, parasite-derived products could serve as potential candidates for treating autoimmune diseases and allergies (). Our previous systematic review summarised evidence indicating that some helminth-derived proteins can reduce intestinal inflammation by upregulating anti-inflammatory cytokines, supporting T regulatory cell function, and improving outcomes in a colitis model (). Parasites and their proteins can have anti-inflammatory effects, but this might be a double-edged sword in cancer. Immunomodulation may promote anti-tumour activity by regulating inflammation and shaping immune responses (, ), but it can also impair immune surveillance and reduce the immune system’s ability to recognise and eliminate malignant cells. However, limited studies have investigated whether these secretory molecules may directly interact with cancer cells, thereby increasing cell survival or promoting proliferation. Strong evidence indicates that cancer-promoting processes are present in Schistosoma haematobium (S. haematobium), Opisthorchis viverrini (O. viverrini), and Clonorchis sinensis (C. sinensis), all of which are associated with persistent infection and foster a microenvironment conducive to malignant transformation (). On the other hand, some parasites or parasite-derived proteins, such as Echinococcus granulosus (E. granulosus), Toxoplasma gondii (T.gondii), and Trypanosoma cruzi (T.cruzi), can enhance the immune response against tumours, inhibit tumour growth, or mimic cancer antigens to stimulate the immune system ().
The dual effect illustrates the complex interactions between parasites and cancer, involving chronic infection, host immune responses, tissue remodelling, and tumour microenvironment dynamics (–). Parasite-derived proteins have also been assessed in vitro for their effects on cancer cell cycle progression, apoptosis, motility, and cytokine responses under controlled conditions (). This paradox underscores the biological and clinical significance of the association between parasites and cancer (). Despite these observations of the paradoxical effect of parasites, they remain scattered across individual experimental models. Moreover, there remains a lack of comprehensive understanding of the common mechanistic pathways across diverse tumour types and parasitic species. Therefore, this study was conducted to evaluate the mechanistic pathways underlying both pro-tumour and anti-tumour effects of parasites or parasite-derived products across different experimental models and to identify shared versus tumour-specific biological patterns across cancer types.
Methodology
Search strategy and study selection
This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement (1) and adhered to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (2). The review protocol was prospectively registered with PROSPERO (Registration ID: 2025 CRD420250656117).
The literature search was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane Library from the databases’ inception to January 2026 (Figure 1). Search terms combined controlled vocabulary (MeSH and Emtree) and free-text keywords related to parasites (e.g., parasite, helminth, protozoa), parasite-derived factors (e.g., excretory–secretory products, parasite-derived proteins, microRNA), and cancer-related outcomes (e.g., cancer, tumorigenesis, carcinogenesis, apoptosis, immune modulation, signalling pathways). Boolean operators, truncation, and alternative spellings were applied to maximise sensitivity.
Figure 1
Eligibility criteria
Studies were eligible if they investigated the direct effects of parasites or parasite-derived molecules on cancer initiation, progression, or regression, using in vitro or in vivo models and reporting mechanistic or biological cancer-related outcomes (e.g., apoptosis, proliferation, tumour growth, or regression).
Exclusion criteria included review articles, editorials, conference abstracts, non–peer-reviewed publications, studies involving non-human parasites, irrelevant experimental models, absence of cancer-related outcomes, or studies limited to diagnostic or immune profiling without tumour endpoints. Articles unavailable in English or without an accessible full text were also excluded.
Study selection
After removal of duplicate records (n = 2), 496 records were screened by title and abstract. Records not addressing parasite–cancer interactions or reporting non-original data were excluded. Eighty-two reports underwent full-text assessment for eligibility; 48 were excluded for predefined reasons (Figure 1). A total of 34 studies were included in the final review.
Risk of bias evaluation
The risk of bias was independently evaluated utilising the SYRCLE Risk of Bias tool tailored for in vivo studies. The assessment encompassed key domains, including selection, performance, detection, attrition, reporting, and other biases. Each domain was classified as low, high, or unclear risk based on the methodological details provided. A total of twenty-three studies were examined. A high risk of bias indicated the potential presence of systematic errors, whereas a low risk suggested a robust methodological approach. An unclear risk signified insufficient information to determine bias. This evaluation underscores common limitations in experimental parasitology and cancer research, particularly in blinding, and highlights the need for improved reporting standards to enhance reproducibility and methodological validity.
Data collection process and data synthesis
Data extraction was performed independently by five reviewers using a standardised extraction form. Discrepancies were resolved by consensus. Extracted data included publication details, parasite species or parasite-derived molecules, cancer type or experimental model, study design, biological source materials, proposed mechanisms of action, measured outcomes, molecular targets or pathways, and the reported effect on cancer progression (pro-tumorigenic or anti-tumorigenic).
Results
Characteristics of included studies
A total of 498 studies were identified, and 34 met the inclusion criteria for this systematic review (Figure 1). These studies evaluated the effects of parasites and parasite-derived products on cancer biology using in vivo, in vitro, and combined experimental approaches. This review showed a wide range of parasites and parasite-derived molecules, including O. viverrini, S. haematobium, Schistosoma mansoni (S. mansoni), Schistosoma japonicum (S. japonicum), Trichinella spiralis (T.spiralis), T. gondii, T. cruzi, Cryptosporidium parvum (C.parvum), Blastocystis spp.(B. spp.), Blastocystis hominis (B. hominis), C. sinensis, Toxocara canis (T. canis), P. falciparum VAR2CSA, and Anisakis spp (A. spp.). The tested parasite-derived products include soluble antigens, excretory–secretory products, extracellular vesicles, lysate antigens, recombinant proteins, peptides, and parasite-derived non-coding RNAs.
The most studied cancer models include cholangiocarcinoma, colorectal, hepatocellular carcinoma, bladder cancer, melanoma, breast cancer, soft tissue sarcoma, and Burkitt lymphoma. The in vivo studies mainly used hamsters, mice, rats, SCID mice, nude mice, and tumour-bearing mouse models, whilst in vitro studies used various cancer cell lines, including CHO, H69, HCT116, HT-29, Caco-2, HepG2, Hepa1-6, SW620, and HUVECs.
In summary, the included studies provided a solid foundation for studying the mechanistic effects of parasite species and products on different cancer types using various experimental models.
Quality of included studies
The quality assessment showed variable risk of bias in animal studies (Figure 2). Most studies showed a low risk of bias for baseline characteristics, including incomplete outcome data and selective outcome reporting, indicating acceptable comparability between groups and limited concerns about missing data or selective reporting. On the other hand, several domains showed a high risk of bias due to methodological limitations, including potential selection, performance, and detection biases. In addition, insufficient reporting of key methodologies, such as random sequence generation, random housing, and random outcome assessment.
Figure 2
The effects of parasites and parasite-derived proteins on tumour promotion and suppression
Overview of included studies
This systematic review included 34 studies. However, because some studies included both in vivo and in vitro experimental designs, these were analysed independently, yielding 38 experimental datasets for effect classification (Table 1). Overall, 26 of 38 datasets (68.4%) reported pro-tumour effects, whereas 12 of 38 datasets (31.6%) showed anti-tumour effects. In the in vivo studies, 17 of 23 studies (73.9%) showed pro-tumour activity, whilst 6 studies (26.1%) reported anti-tumour activity. Similarly, in the in vitro studies, 9 of 15 studies (60%) showed pro-tumour effects, whereas 6 studies (40%) showed anti-tumour effects.
Table 1
| Study | Year | Parasite/parasite product | Cancer type | Study type | Model/cell liens | Control |
|---|---|---|---|---|---|---|
| () | 1978 | O. viverrini | CCA | In vivo | Hamster | Untreated control; DMN alone control; Parasite alone control |
| () | 1987 | O. viverrini | CCA | In vivo | Hamster | Untreated control; Parasite-only controls (various doses); Carcinogen-only controls (various doses) |
| () | 1988 | O. viverrini | CCA and hepatocellular nodules | In vivo | Hamster | Untreated control; Nitrite control; Aminopyrine control; Parasite control |
| () | 1988 | O. viverrini | Liver and Pancreatic cancer | In vivo | Hamster | Basal diet control; BHA alone control; DHEA alone control; Parasite + diet controls |
| () | 1992 | T. gondii-lysate antigen | Soft tissue sarcoma | In vivo | Rat | Untreated tumour control; Saline control |
| () | 1994 | O. viverrini | CCA | In vivo | Hamster | DMN alone control; OV alone control; Untreated control |
| () | 1996 | O. viverrini | CCA and HCC | In vivo | Hamster | Untreated control (0 metacercariae); Noninfected control (BrdU analysis) |
| () | 1998 | O. viverrini | CCA and hepatocellular lesions | In vivo | Hamster liver tissue | Disease model control; Vehicle control |
| () | 2001 | T. cruzi | CRC | In vivo | Rat | Chemical carcinogen-treated control; non- immunised control |
| () | 2009 | O. viverrini | CCA | In vivo | Hamster/tissue | Normal control; NDMA alone control; Infection alone control |
| () | 2009 | S. haematobium antigen | Subcutaneous sarcoma | In vivo | nude mice | Untreated control animal group |
| () | 2009 | S. haematobium antigen | SCC | In vitro | CHO cells | Untreated control cells (multiple assays) |
| () | 2011 | O. viverrini | CCA | In vivo | Parasite infection model | Normal group; Infection alone group; NDMA alone group |
| () | 2011 | S. haematobium antigen | bladder cancer | In vivo | Mouse urothelium | Vehicle control (saline) |
| () | 2012 | B. hominis antigens | CRC | In vitro | HCT116 cells | Untreated control; Positive control (mitogen) |
| () | 2012 | C. parvum | Digestive adenocarcinoma | In vivo | SCID mouse | Negative control (PBS); Negative control (inactivated oocysts) |
| () | 2013 | S. mansoni | HCC | In vivo | Mouse | Control animals; Untreated control cells |
| () | 2013 | S. haematobium-SEA | Tumour-like phenotypes in urothelial cells | In vitro | HCV29 cells | S. mansoni infection only control; Healthy control |
| () | 2015 | T. spiralis and T. spiralis-ES L1 antigens | Melanoma | In vitro/In vivo | B16 cells/mouse | Uninfected control animals (in vivo); Untreated melanoma cells (in vitro) |
| () | 2015 | O. viverrine-Ov-GRN-1 | CCA | In vitro/In vivo | Cell lines/mouse | Control recombinant protein (rTRX); Control dsRNA-treated flukes; Vehicle control (PBS); Baseline control |
| () | 2015 | O. viverrine EVs | CCA | In vitro/In vivo | H69 cells/mouse | Uninfected control hamsters; ES products control; BSA negative control; Medium alone control |
| () | 2015 | B.spp. ST-1 | CRC | In vitro | HT-29 cells | Untreated control |
| () | 2015 | P. falciparum-VAR2CSA protein | BL | In vitro | BL cell lines/tissue | Endemic controls; Technical controls; Specificity controls; Protein control; Negative controls |
| () | 2016 | O. viverrini ES | CCA | In vitro | H69/CaCo-2 cells | Untreated control |
| () | 2017 | O. viverrini Ov-GRN-1 | CCA | In vitro | HUVECs | Medium-alone control; Blank control; Negative control (anti-angiogenic); Positive control (pro-angiogenic) |
| () | 2017 | C. sinensis ES | CCA | In vitro | H69 cells | Untreated control; Vehicle control (PBS); Negative control siRNA; Liposome-only control |
| () | 2018 | S. mansoni-antigen extract and T. spiralis-antigen extract | CRC | In vivo | Mouse | Untreated control; Cancer control; ASMA control; ATSA control |
| () | 2019 | S. japonicum MicroRNA Sja-miR-3096 derived from | HCC | In vitro/In vivo | Hepa1-6/SMMC-7721/nude mice | Negative control mimics; Blank control; EV extraction control; Uninfected group; Empty plasmid control; Vehicle control (PBS); NC siRNA |
| () | 2020 | T. canis | Breast cancer | In vivo | 4T1 mouse | Tumour-only control |
| () | 2020 | S. mansoni eggs + SEA (SEA) + IPSE/α-1 | CRC | In vitro | SW620/hamster/biopsy | DMN alone control; OV alone control; Untreated control |
| () | 2021 | S. japonicum microRNA (sja-miR-61) | HCC | In vitro/In vivo | Hepa1-6/HepG2/HUVEC/mice | Negative control mimic; Mock control; NC siRNA; Empty vector control; NC-transfected cells; Uninfected mice |
| () | 2021 | C. parvum | CRC | In vivo | SCID mouse mice ileo-cecal tissue | Uninfected control |
| () | 2024 | T. gondii-GRA1-derived peptide | CRC | In vitro | Caco-2/HT29/HepG2 | Carcinogen alone control; Parasite alone control; Untreated control |
| () | 2024 | A. spp-EVs | CRC | In vitro | intestinal organoids | PBS |
Characteristics of the included studies investigating parasite- and parasite-derived factors in cancer models.
TLA, T. gondii lysate antigen; DHEA, dehydroepiandrosterone; BHA, butylated hydroxyanisole; CHO, Chinese hamster ovary; SCID, severe combined immunodeficiency; Sh-SEA/SEA, soluble egg antigen; ESP, excretory-secretor; ES L1, excretory-secretory antigens from muscle larvae; EVs, extracellular vesicles; BL, Burkitt lymphoma; CCA, cholangiocarcinoma; CRC, Colorectal cancer; HCC, Hepatocellular carcinoma; SCC, Squamous cell carcinoma; HUVECs, human umbilical vein endothelial cells; NDMA, N-nitrosodimethylamine.
Mechanistically, the pro-tumour effects were grouped into four categories: coinfection or co-carcinogenesis, chronic infection-associated carcinogenesis, immune modulation that favours tumour progression, and activation of oncogenic signalling pathways. In contrast, the anti-tumour effects were classified into three main mechanisms: induction of apoptosis, inhibition of tumour migration and angiogenesis, and activation of anti-tumour immune responses.
In vitro effects of parasites and parasite-derived proteins on tumour promotion and suppression
The analysis of 15 in vitro studies (Table 2) revealed a complex, often dichotomous relationship between parasitic organisms and cancer, demonstrating that parasite-derived molecules can promote or suppress tumorigenic phenotypes. The majority of the studies (9 out of 15) showed a pro-tumorigenic effect through immune modulation and activation of oncogenic pathways.
Table 2
| Pro-tumour effects (n = 9 studies) | ||||||
|---|---|---|---|---|---|---|
| Ref | Parasite/protein | Target cancer (Clinical) | Cell line/model | Key mechanisms | Outcomes measured | Molecular targets |
| Immune modulation | ||||||
| () | B. hominis antigens | Colorectal cancer | HCT116 cells | ↑Proliferation, ↑ Th2 cytokines expression | MTT viability, gene expression | ↑TNF-kB, ↑Th2 cytokines, ↑Cathepsin B |
| Activation of oncogenic pathways | ||||||
| () | O. viverrini Ov-GRN-1 | Cholangiocarcinoma | H69 cholangiocytes | ↑Proliferation, | Scratch assays, proliferation, migration | ↑CXCL1/2/8-CXCR2- EGFR-MAPK axis |
| () | O. viverrini EVs | Cholangiocarcinoma | H69 cholangiocytes | EV internalization, ↑proliferation | Cell proliferation, IL-6 secretion | ↑MAPK signalling, ↑IL-6 |
| () | O. viverrini ES products | Cholangiocarcinoma | H69, Caco-2 cells | ↑Glycolysis, ER stress | Proteomic analysis | Glycolysis/gluco- neogenesis pathways |
| () | O. viverrini Ov-GRN-1 | Cholangiocarcinoma | HUVECs | ↑Angiogenesis, ↑endothelial proliferation | Proliferation, tubule formation | Angiogenesis stimulation |
| () | Clonorchis sinensis ESP + NDMA | Cholangiocarcinoma | H69 cholangiocytes | ↑Proliferation, G2/M phase shift | Cell proliferation, cell cycle | ↑Connexin 43/26, ↑E2F1, ↑Ki-67 |
| () | S. mansoni eggs/SEA/IPSE | Colorectal cancer | SW620 cells | Wnt/β-catenin activation, JNK/c-Jun pathway | β-catenin, AP-1 reporter, proliferation | ↑Wnt/β-catenin, ↑ c-Jun/AP-1, ↑Cyclin D1 |
| () | S. haematobium total antigen | Squamous cell carcinoma | CHO cells | ↑Proliferation, ↑migration, ↑invasion, ↓apoptosis | Cell proliferation, apoptosis, migration, invasion | ↑Bcl-2, ↓p27, cell cycle disruption |
| () | Anisakis spp. EVs | Colorectal cancer | Human intestinal organoids | ↓Tumour suppressors | RNA-seq, qRT-PCR, cytokine profiling | ↓EPHB2, ↓LEFTY1, ↑NUPR1 |
| Anti-tumour effects (n = 6 studies) | ||||||
|---|---|---|---|---|---|---|
| Ref | Parasite/protein | Target cancer (clinical) | Cell line/model | Key mechanisms | Outcomes measured | Molecular targets |
| Direct tumour cell cytotoxicity and growth suppression | ||||||
| () | T. spiralis ES L1 | Melanoma | B16 melanoma cells | ↑Apoptosis (extrinsic pathway) | Cell survival, apoptosis assays | ↑Caspase-3, ↑Caspase-8 |
| () | B.spp. ST-1 | Colorectal cancer | HT-29 cells | Retinoic acid pathway modulation | Gene expression arrays, qRT-PCR | ↑CRABP2, ↓PCNA, ↑RARα |
| () | P. falciparum VAR2CSA | Burkitt lymphoma | Burkitt lymphoma cell lines | Oncofetal chondroitin sulphate targeting | Binding assays, cytotoxicity | Oncofetal chondroitin sulphate A |
| () | T. gondii peptides | Colorectal + Hepatocellular carcinoma | Caco-2, HT29, HepG2 | ↑Apoptosis | MTT viability, flow cytometry | ↓Bcl-2, ↓APAF1, cytochrome c/caspase cascade |
| Inhibition of migration | ||||||
| () | S. japonicum miR-3096 | Hepatocellular carcinoma | Hepa1-6, SMMC-7721 | ↓Proliferation, ↓migration, G0/G1 arrest | Proliferation, colony formation, migration | ↓PIK3C2A -> ↓mTOR signalling |
| () | S. japonicum miR-61 | Hepatocellular carcinoma | Hepa1-6, HepG2, HUVECs | ↓Migration, ↓angiogenesis | Migration assays, angiogenesis markers | ↓PGAM1 (glycolytic enzyme) |
In vitro studies of parasite and parasite-derived proteins on cancer.
B. hominis antigens enhanced the proliferation of colorectal cancer cells and the expression of Th2-associated cytokines, indicating a pro-tumour immunomodulatory effect (). Four studies examined the pro-tumorigenic effects of O. viverrini-derived products on biliary and endothelial cell lines. O. viverrini extracellular vesicles were internalised by H69 cholangiocytes, driving cell proliferation and Interleukin-6 (IL-6) secretion through MAPK signalling activation (). Another study reported that O. viverrini Ov-GRN-1 promoted both proliferation and migration of H69 cholangiocytes through the CXCL1/2/8-CXCR2-EGFR-MAPK signalling axis, as confirmed by scratch and proliferation assays (). A subsequent proteomic study demonstrated that O. viverrini excretory-secretory products reprogrammed metabolism in H69 and Caco-2 cells, inducing endoplasmic reticulum stress and upregulating glycolysis and gluconeogenesis pathways (). O. viverrini Ov-GRN-1, extracellular vesicles, and ES products promoted cholangiocyte proliferation, migration, angiogenesis, and metabolic reprogramming (). Moreover, C. sinensis excretory-secretory products and the carcinogen NDMA induced cell-cycle progression by upregulation of Ki-67, E2F1, and connexin 43/26 (). S. mansoni eggs, soluble egg antigen, and IPSE activated the Wnt/β-catenin and JNK/c-Jun pathways in SW620 colorectal cancer cells through activated Wnt/β-catenin and JNK/c-Jun signalling (). S. haematobium total antigen enhanced proliferation and migration whilst reducing apoptosis in CHO cells, whilst suppressing apoptosis, mediated through Bcl-2 upregulation, p27 downregulation, and cell cycle disruption (). Using human intestinal organoids, Anisakis extracellular vesicles suppressed tumour suppressor pathways by downregulating the tumour suppressors EPHB2 and LEFTY1 and upregulating NUPR1 ().
Conversely, a subset of studies highlights the potent anti-tumorigenic activities of parasite-derived molecules (6 out of 15). ES products from the nematode T. spiralis, for example, induce apoptosis in melanoma cells via the extrinsic pathway, involving the activation of caspases 8 and 3 (). In a similar vein, peptides derived from T. gondii trigger mitochondrial-dependent apoptosis in colorectal and liver cancer cell lines by downregulating Bcl-2 and upregulating the apoptosis-promoting factor APAF1 (). Research on S. japonicum has identified specific microRNAs with significant anti-cancer properties (, ). Notably, Sja-miR-3096 inhibits hepatoma cell proliferation and induces G0/G1 cell cycle arrest by targeting PIK3C2A, thereby suppressing the mTOR signalling pathway. Another microRNA, sja-miR-61, inhibits hepatoma cell migration and angiogenesis by directly targeting phosphoglycerate mutase 1 (PGAM1). In colorectal cancer models, lysates from B.spp. ST-1 were found to modulate retinoic acid signalling pathways by upregulating CRABP2 and RARα, which, in turn, led to downregulation of the proliferation marker PCNA and reduced cell growth (). The VAR2CSA, a surface protein of P. falciparum, selectively bound Burkitt lymphoma cell lines via oncofetal chondroitin sulphate, thereby demonstrating direct tumour cell killing by exploiting the aberrant re-expression of this placenta-restricted glycosaminoglycan on malignant lymphoma cells ().
In summary, in vitro evidence underscores the context-dependent and molecule-specific roles of parasitic factors in carcinogenesis. While many parasite-derived components clearly promote established hallmarks of cancer, including sustained proliferation, angiogenesis, and immune evasion, others exhibit strong antiproliferative and proapoptotic effects. This dual functionality suggests that specific parasite molecules could serve not only as etiological agents in infection-associated cancers but also as a novel source of targeted therapeutic agents.
In vivo effects of parasitic infection and parasite-derived molecules on cancer
The in vivo studies comprise 23 studies utilising different murine and hamster models (Table 3). Most in vivo studies reported tumour-promoting outcomes (17 of 23), frequently in the presence of chemical or viral cofactors. O. viverrini infection was consistently associated with cholangiocarcinoma in animal models, with tumour incidence approaching 100% in Syrian golden hamsters co-exposed to carcinogens such as dimethylnitrosamine (DMN) or N-nitrosodimethylamine (NDMA) (–, –). Pathological features included chronic inflammation, cholangiofibrosis, and epithelial dysplasia, accompanied by activation of Wnt/β-catenin and MAPK signalling, and increased expression of ERBB2 and Transforming Growth Factor-Beta1 (TGF-β1). Chronic infection with S. haematobium () and S. mansoni () induces urothelial inflammation and dysplasia in bladder tissues and hepatocellular carcinoma, respectively, in a murine model. This effect is mainly observed through the generation of reactive oxygen and nitrogen species (ROS/RNS)- mediated DNA damage, including P53 gene mutations.
Table 3
| Pro-tumour effects (n = 17 studies) | ||||||
|---|---|---|---|---|---|---|
| Ref | Parasite/protein | Cancer type/model | Animal model | Key mechanisms | Outcomes measured | Molecular Targets |
| Chronic Infection and co-carcinogenesis | ||||||
| () | O. viverrini | Cholangiocarcinoma | Syrian golden hamsters | Synergistic carcinogenesis with DMN | Cholangiocarcinoma incidence (100%) | DMN acts on parasite-altered epithelium |
| () | O. viverrini | Cholangiocarcinoma | Syrian golden hamsters | Dose-dependent tumour promotion | Cholangiocarcinoma incidence, histopathology | Parasite-enhanced DMN carcinogenesis |
| () | O. viverrini | Cholangiocarcinoma and HCC | Syrian golden hamsters | Synergistic effect with nitrite/aminopyrine | Tumour incidence, histopathology | Nitrosamine formation with inflammation |
| () | O. viverrini | Cholangiocarcinoma | Syrian golden hamsters | Chronic inflammation, epithelial proliferation | Cholangiocarcinoma incidence/severity | DMN and parasite-induced inflammation |
| () | O. viverrini | Cholangiocarcinoma and HCC | Syrian golden hamsters | Chronic irritation, increased cell turnover | Proliferative lesions, cholangiofibrosis | Tumour-promoting chronic inflammation |
| () | O. viverrini | Cholangiocarcinoma and HCC | Syrian golden hamsters | Parasite clearance effects, chemoprevention | Lesion counts, liver weights | Inflammatory modulation, DHEA pathway |
| () | S. haematobium | Bladder cancer | CD-1 mice | Chronic inflammation, ROS/RNS generation | Urothelial dysplasia, inflammatory infiltrate | Reactive oxygen/nitrogen species |
| () | S. mansoni | Hepatocellular carcinoma | Swiss albino mice | Synergistic hepatocarcinogenesis with DEN | Liver dysplasia, AFP/ferritin, survival | Chronic inflammation, p53 mutation |
| () | C. parvum | Digestive adenocarcinoma | CB17-SCID mice | Chronic infection, epithelial transformation | Neoplastic lesions, parasite burden | Infection-driven proliferation, immune evasion |
| Immune modulation | ||||||
| () | O. viverrini | Liver and Pancreatic cancer | Syrian golden hamsters | Immune modulation, GST-P induction | Lesion count, GST-P expression | GST-P expression, bile duct proliferation |
| () | S. haematobium total antigen | Subcutaneous sarcoma | Nude mice xenograft (subcutaneous CHO inoculation) | Schistosomal antigens → fibroblast stimulation → sarcoma formation | Gross tumourigenesis | Granuloma → cytokines/growth factors → fibroplasia |
| () | T. canis | Breast cancer | BALB/c mice | Tumour immune microenvironment modulation | Tumour size/weight, immune populations | ↑Th2, macrophages, ↓CD8+ T cells |
| () | C. parvum | Colorectal cancer | CB17-SCID mice | Immune modulation, tumour microenvironment | Adenocarcinoma development, gene expression | ↓α-defensins, Wnt/NF-κB/Hedgehog pathways |
| Activation of oncogenic pathways | ||||||
| () | O. viverrini | Cholangiocarcinoma | Syrian golden hamsters | RB pathway disruption | Gene expression, histopathology | ↓RB1, ↓p16INK4, ↑cyclin D1, CDK4 |
| () | O. viverrini | Cholangiocarcinoma | Syrian golden hamsters | Dysregulated gene expression, oncogenesis | Transcriptomic profiling, histology | ↑ERBB2, ↑MMP9, ↑TGF-β1, MAPK/Wnt signalling |
| () | O. viverrini Ov-GRN-1 | Cholangiocarcinoma | BALB/c mice | Epithelial proliferation, angiogenesis | Wound closure, angiogenesis, gene expression | ↑CXCL1/2/8–CXCR2–EGFR–MAPK axis |
| () | S. haematobium | Bladder cancer | CD-1 mice | Oestrogen-DNA adducts, oxidative stress | Proliferation, apoptosis, DNA damage | Catechol-oestrogens, DNA adduct formation |
| Anti-tumour effects (n = 6 studies) | ||||||
|---|---|---|---|---|---|---|
| Ref | Parasite/protein | Cancer type/model | Animal model | Key mechanisms | Outcomes measured | Molecular targets |
| Apoptosis | ||||||
| () | T. spiralis ES L1 | Melanoma | C57BL/6 mice | Apoptosis induction, necrosis suppression | Tumour volume, necrosis/apoptosis % | Caspase-3/8 dependent apoptosis |
| Inhibition of migration | ||||||
| () | S. japonicum miR-3096 | Hepatocellular carcinoma | BALB/c nude mice | miR-3096 suppresses via PIK3C2A/mTOR | Tumour volume/weight reduction | ↓PIK3C2A → ↓mTOR signalling |
| () | S. japonicum miR-61 | Hepatocellular carcinoma | C57BL/6J mice | Migration/angiogenesis inhibition via PGAM1 | Tumour volume/weight, CD34, migration | ↓PGAM1, anti-angiogenesis |
| Immune activation | ||||||
| () | T. gondii TLA | Fibrosarcoma | Wistar rats | Immune modulation, Thy-1+ cell activation | Tumour growth inhibition, immune infiltration | Thy-1+ cells, host immune response |
| () | T. cruzi | Colorectal cancer | Wistar rats | Immune modulation, host resistance | Colon tumour incidence, histopathology | Systemic immune modulation |
| () | S. mansoni and T. spiralis | Colorectal cancer | Swiss albino mice | Immune modulation, regulatory T cells | Tumour size, cytokine levels, Treg cells | ↑FoxP3+ Tregs, ↓IL-17, ↑IL-10 |
In vivo studies of parasite and parasite-derived proteins on cancer.
In addition, 4 studies showed that immunomodulation promotes carcinogenesis, including O. viverrini (), S. haematobium total antigen (), T. canis (), and C. parvum (). O. viverrini promoted liver and pancreatic lesions with increased GST-P expression, which is an immune modulatory effect, and bile duct proliferation, whilst S. haematobium tatal antigen enhanced sarcoma formation through fibroblast stimulation, granuloma-related cytokines, and fibroplasia. T. canis induces breast cancer by shifting the tumour microenvironment towards Th2 responses and suppressing CD8+ T cells. In addition, C. parvum promoted CRC development in SCID mice, leading to alterations in immune and cancer-related signalling pathways.
Moreover, some parasites may promote tumour progression by activating or disrupting cancer-related signalling pathways. O. viverrini was linked to cholangiocarcinoma through RB pathway disruption, reduced RB1 and p16INK4 expression, and increased cyclin D1/CDK4 activity (). Other O. viverrini models showed dysregulated oncogenic gene expression involving ERBB2, MMP9, TGF-β1, MAPK, and Wnt signalling (). S. haematobium promoted bladder cancer through oestrogen-DNA adduct formation, oxidative stress, and DNA damage (). In addition, O. viverrini Ov-GRN-1 enhanced epithelial proliferation and angiogenesis through the CXCL1/2/8–CXCR2–EGFR–MAPK axis. Overall, these results indicate that parasite-associated oncogenic signalling may drive proliferation, DNA damage, angiogenesis, and malignant transformation ().
A limited number of in vivo studies (6/23) showed antitumour activity through apoptosis, migration inhibition, and immune activation. T. spiralis ES L1 reduced melanoma growth by inducing caspase-3/8–dependent apoptosis (). S. japonicum miR-3096 and miR-61 inhibited hepatocellular carcinoma growth by reducing tumour volume, migration, and angiogenesis through suppression of PIK3C2A/mTOR and PGAM1-related pathways (, ). In addition, T. gondii TLA (), T. cruzi (), and combined S. mansoni/T. spiralis () exposures showed anti-tumour activity through an immunoregulatory mechanism in which FoxP3+ Treg expansion and Interleukin-10 (IL-10) elevation suppressed pro-tumorigenic chronic colonic inflammation, as evidenced by a significant reduction in IL-17.
In summary, most findings supported a pro-tumour effect of parasite infection. The in vivo evidence indicates that chronic infection, persistent inflammation, oxidative stress, and immune deregulation are the major drivers of parasite-induced tumour progression. On the other hand, limited studies found that parasite-derived products may exert antitumour effects by acting as immunomodulatory factors that suppress tumour growth, enhancing immune cell infiltration and inducing molecular mimicry or cross-reactivity against tumour-associated antigens.
Discussion
This study aimed to examine the mechanisms underlying the dual effects of parasites and their products on cancer across different experimental models. The results reveal a dual role in cancer biology. Observations from 34 studies suggest that both protumour and antitumour effects are influenced by parasite dependence, chronicity, and the host environment (Figure 3). The studies showed that the parasites may promote cancer progression through various mechanisms, including chronic inflammation, co-infection, co-carcinogenesis, and immunomodulation. Conversely, they exert anti-tumour effects through direct cytotoxicity, immune activation and surveillance, and molecular modulation.
Figure 3
This study highlights that chronic infection acts as a direct carcinogen. For instance, chronic infection of S. haematobium promotes bladder carcinoma, and S. mansoni promotes hepatocellular carcinoma through sustained ROS/RNS-mediated genotoxic damage, demonstrating that protracted parasite-driven inflammation is sufficient to initiate malignant transformation independently of other risk factors (, , ). Several in vitro studies provide molecular evidence of the specific signalling pathways, such as MAPK, NF-κB, Cyclin D1, and MCM2, that drive neoplastic transformation. This molecular profile may promote cell cycle progression, DNA replication, and resistance to apoptosis (–). Moreover, the co-infection context further amplifies the inflammatory cascade. A previous study reviewed the mechanism by which O. viverrini infection interacts with bacterial infection (Helicobacter pylori), thereby increasing the risk of developing CCA (). P. falciparum promotes the expansion of Epstein-Barr virus (EBV)-infected B-cells, enhances AID-driven DNA damage, and raises the risk of c-MYC translocation, all of which contribute to the development of Burkitt’s lymphoma (). In addition, this study suggests that parasitic infection could accelerate the development of cancer in the presence of carcinogens. Here we report that early studies on O. viverrini act synergistically with nitrosamine carcinogens, including DMN and NDMA, to induce tumours. NDMA has emerged as a major environmental contaminant, originating from both human activities and natural sources (, ). Ten studies published between 1978 and 2008 showed that co-exposure to O. viverrini and nitrosamine carcinogens consistently induced cholangiocarcinoma in animal models, with tumour incidence reaching 100%, whereas exposure to either agent alone was insufficient to produce comparable carcinogenic effects (–, –, , , ). This data indicates that parasites might not primarily act as carcinogenic initiators but rather as powerful tumour promoters that enhance the oncogenic potential of pre-existing DNA damage.
The oncological effects of parasitic infection vary and are not predictable. They depend on the parasite species, duration of infection, and the host’s immune response. Persistent Th2 environments tend to promote tumour growth, whilst acute Th1-polarised responses activate anti-tumour immunity (). A previous review sharpens this picture by concluding that cancer cells mirror helminth survival strategies such as immunoevasion, metabolic adaptation, tissue remodelling, and host manipulation, which partly explains why those responses can be either tumoricidal or tolerogenic (). This study summarised that the pro-tumour effects were associated with inflammatory and immunoregulatory changes, including increased Th2 responses, macrophage involvement, reduced CD8+ T-cell activity, and remodelling of the tumour microenvironment, as reported with B. hominis, O. viverrini (), T. canis (), Anisakis spp (), and C. parvum (). Parasite-associated immune environments recruit and activate the same cellular components as those involved in cancer-associated immune remodelling: group 2 innate lymphoid cells (ILC2s), M2-polarised macrophages, eosinophils, and Tregs. During chronic parasitic infection, epithelial cells release IL-33, TSLP, and IL-25, which sustain ILC2 activation and Th2 differentiation, thereby generating a cytokine environment dominated by IL-4, IL-5, and IL-13 (). This drives M2 macrophage polarisation, marked by arginase-1, CD163, and CD206, and is associated with downstream production of TGF-β, VEGF, and CCL17/CCL22. Within the tumour microenvironment, M2-polarised Tumour-Associated Macrophages (TAMs) facilitate vascular remodelling, extracellular matrix turnover, and suppression of CD8+ T cells through mechanisms nearly identical to the wound-healing programmes parasites exploit for persistence (–). ILC2-derived IL-13 amplifies M2 phenotype and expands Myeloid-derived suppressor cells (MDSCs); parasite-induced Tregs, acting through IL-10 and TGF-β, further suppress checkpoint responsiveness. Fibroblast activation, collagen deposition, and sustained angiogenesis are shared features of chronic parasitic infection and tumour stroma alike, which explains the resemblance that persistent type 2 environments are permissive for tumour growth (). However, the prevailing assumption that Th2 immunity promotes tumorigenesis has been challenged. Wagner, Nishikawa, and Koyasu reviewed that Th2 responses can, depending on host and microenvironmental context, actively suppress tumour (). For instance, IL-5-recruited eosinophils can kill tumour cells directly through major basic protein, eosinophil peroxidase, and granzyme A (), and their infiltration correlates with favourable prognosis in colorectal cancer (, ). Here, we highlighted that antitumour effects were associated with immune activation, immune cell infiltration, and enhanced host resistance, particularly in studies involving T. gondii () and T. cruzi (). Th2 cytokines also promote eosinophil recruitment to tumours (), and IL-4 deficiency impairs tumour clearance in experimental models (). ILC2s, as a primary source of tumour-associated IL-4, can support CD8+ cytotoxic function, as demonstrated by IL-4 signalling via STAT6 and mTOR revitalising exhausted CD8+ T cells in the tumour microenvironment (). This functional plasticity is precisely what underlies the species- and host-dependent paradox described in this review.
In addition, the reported modulation of FoxP3+ regulatory T cells, IL-10, and IL-17 in S. mansoni and T. spiralis models suggests that parasite-driven immune regulation can shift the tumour environment towards either tumour promotion or tumour suppression, depending on the parasite species, cytokine profile, and experimental cancer model. (). Parasites that induce a chronic environment dominated by IL-10 and TGF-β reinforce tumour immune evasion strategies. In contrast, parasites that are associated with acute or self-limiting infections can promote anti-tumorigenic immune responses (, ). In the context of IL-10, for example, our previous study concluded that IL-10 may have a dual role in cancer biology, possibly due to the heterogeneity of CRC, which encompasses subtypes defined by molecular signatures. (). Interpreting parasite-cancer interactions therefore requires identifying not only which organism is involved but also which type 2 immune modules are active, in which tissue compartment, and at which stage of tumour development.
Parasite-derived molecules may exhibit anti-tumour activity that differs from that observed during natural infection, as isolated parasite products can selectively modulate immune responses without inducing the chronic inflammation or tissue damage associated with live infection. For example, S. japonicum infection can influence macrophage polarisation, shifting from M1 during acute infection to M2 in chronic stages (). Additionally, schistosome worm antigen (SWA) promotes M1, whereas schistosome soluble egg antigen (SEA) favours M2, depending on the infection stage and the antigen involved (). However, S. japonicum non-coding RNA, such as miR-3096 and miR-61, shows anti-tumour effects by inhibiting migration (, ). Another example is seen in P. falciparum malaria infection, which can activate B cells through PfEMP1/CIDR1α, promoting polyclonal B-cell expansion and increasing the pool of EBV-infected B cells at risk of malignant transformation (). However, using P. falciparum VAR2CSA induces an anti-tumour effect in Burkitt lymphoma by targeting oncofetal chondroitin sulphate, which is highly expressed in Burkitt lymphoma ().
Limited studies indicate that parasite-derived molecules can exert biological effects in cancer models beyond the parasite’s original infection niche, supporting their potential as novel therapeutics. For instance, T. spiralis ES L1 in melanoma () and T. gondii-derived peptides in colorectal and hepatocellular cancer models (). This provides preliminary evidence that some parasite-derived products could be explored as potential therapeutic or mechanistic tools in cancer research.
Immunosuppression resulting from infectious diseases, malnutrition, or chemotherapy increases susceptibility to opportunistic parasitic infections (). Compromised immune function may allow persistent parasitic infections, leading to chronic inflammation, tissue damage, and disrupted immune signalling, which can contribute to cancer development and disease progression. The prevalence of intestinal parasitic infections such as Cryptosporidium spp. and T. trichiura amongst HIV patients is 19.6%, highlighting the importance of regular screening and treatment for intestinal parasitic infections in individuals with HIV/AIDS (). Moreover, a previous systematic review and meta-analysis found that 28.4% of cancer patients had intestinal parasites, mainly B. hominis and C. parvum (). Another systematic review found that 19.7% of CRC patients had intestinal parasites such as Cryptosporidium spp. and a much higher risk (OR 3.61) of developing CRC than healthy people (). Here, a study showed that a low dose of C. parvum oocysts, confirmed by qPCR, induces digestive adenocarcinoma (). Persistent C. parvum infection promotes an immunosuppressive tumour environment through immunosuppressive cells and pro-inflammatory mediators ().
Several limitations impact the interpretation of these findings. Most notably, the predominance of dated in vivo studies may reflect the technical challenges of parasite–tumour co-infection models, ethical restrictions, high costs, and host variability. The reviewed research showed significant methodological differences, including the use of various parasite species or products, animal models, cell lines, carcinogens, and endpoints, making direct comparisons difficult. Furthermore, publication bias and the lack of extensive human clinical validation limit the applicability of the results, particularly regarding the therapeutic use of parasite-derived molecules. Humanised mouse models may enhance the translational relevance of in vivo parasite-cancer studies. Future epidemiological research combining parasitological and cancer incidence data could help establish human correlations. Additionally, detailed analysis and recombinant production of parasite proteins may be crucial for developing anti-tumour secretomes.
In conclusion, in vitro and in vivo studies indicate that parasites and parasite-derived proteins can exert protumour and antitumour effects, determined by parasite species, infection chronicity, and host immune context. Chronic infection can promote tumour development by inducing M2 macrophage polarisation, expanding Treg and Th2 cells, and sustaining the signalling of anti-inflammatory cytokines such as IL-10 and TGF-β. In addition, chronic infection leads to desmoplastic stromal remodelling, which supports immune evasion by cancer cells. In contrast, acute infection or infections that are immunologically resolved can activate tumour-killing immune responses. These responses include immune-mediated cytotoxicity, polarisation towards Th1 cells, induction of tumour cell apoptosis, and inhibition of tumour cell migration. Collectively, these findings underscore that the parasite-cancer relationship is governed by the microenvironment. This provides a rationale for investigating parasite-derived molecules as potential therapeutic candidates, although mechanistic precision is required prior to clinical translation.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Author contributions
FM: Conceptualization, Formal analysis, Investigation, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing, Funding acquisition, Project administration. MA: Data curation, Formal analysis, Investigation, Validation, Project administration, Writing – original draft. HA: Data curation, Methodology, Validation, Writing – review & editing. AD: Data curation, Methodology, Resources, Writing – review & editing, Investigation. BA: Data curation, Methodology, Validation, Writing – review & editing, Investigation. SK: Data curation, Methodology, Validation, Writing – review & editing, Investigation. HG: Formal analysis, Investigation, Validation, Writing – review & editing, Data curation. IA: Investigation, Methodology, Resources, Writing – review & editing, Validation. SA: Methodology, Validation, Writing – review & editing, Investigation. TO: Data curation, Methodology, Writing – review & editing, Investigation, Resources. AZ: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Supervision, Validation.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This research work was funded by Umm Al-Qura University, Saudi Arabia under grant number: 26UQU4280261GSSR01.
Acknowledgments
The authors extend their appreciation to Umm Al-Qura University, Saudi Arabia, for funding this research work through grant number: 26UQU4280261GSSR01.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. Generative AI was used solely for language editing and improving readability. The authors reviewed and verified all content and take full responsibility for the final manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
FilhoAMLaversanneMFerlayJColombetMPinerosMZnaorAet al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. (2025) 156:1336–46. doi: 10.1002/ijc.35278
2
HyndmanIJ. Review: the contribution of both nature and nurture to carcinogenesis and progression in solid tumours. Cancer Microenviron. (2016) 9:63–9. doi: 10.1007/s12307-016-0183-4
3
WuSZhuWThompsonPHannunYA. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun. (2018) 9:3490. doi: 10.1038/s41467-018-05467-z
4
De MartelCGeorgesDBrayFFerlayJCliffordGM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. (2020) 8:e180–90. doi: 10.1016/s2214-109x(19)30488-7
5
ParkinDM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. (2006) 118:3030–44. doi: 10.1002/ijc.21731
6
Dalton-GriffinLKellamP. Infectious causes of cancer and their detection. J Biol. (2009) 8:67. doi: 10.1186/jbiol168
7
SamarasVRafailidisPIMourtzoukouEGPeppasGFalagasME. Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries. (2010) 4:267–81. doi: 10.3855/jidc.819
8
HewitsonJPGraingerJRMaizelsRM. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol. (2009) 167:1–11. doi: 10.1016/j.molbiopara.2009.04.008
9
WuZWangLTangYSunX. Parasite-derived proteins for the treatment of allergies and autoimmune diseases. Front Microbiol. (2017) 8:2164. doi: 10.3389/fmicb.2017.02164
10
AlghanmiMMinshawiFAltorkiTAZawawiAAlsaadyINaserAYet al. Helminth-derived proteins as immune system regulators: a systematic review of their promise in alleviating colitis. BMC Immunol. (2024) 25:21. doi: 10.1186/s12865-024-00614-2
11
El SkhawyNShehataAEissaMM. Parasites' immunomodulators: a breakthrough in immunotherapeutics displaying antineoplastic activity against human colorectal and hepatocellular carcinoma cells. Infect Agent Cancer. (2025) 21:5. doi: 10.1186/s13027-025-00715-6
12
ManiRMartinCGBaluKEWangQRychahouPIzumiTet al. A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer. Cells. (2024) 13:111. doi: 10.3390/cells13020111
13
FriedBReddyAMayerD. Helminths in human carcinogenesis. Cancer Lett. (2011) 305:239–49. doi: 10.1016/j.canlet.2010.07.008
14
CallejasBEMartinez-SaucedoDTerrazasLI. Parasites as negative regulators of cancer. Biosci Rep. (2018) 38:BSR20180935. doi: 10.1042/bsr20180935
15
Van TongHBrindleyPJMeyerCGVelavanTP. Parasite infection, carcinogenesis and human Malignancy. EBioMedicine. (2017) 15:12–23. doi: 10.1016/j.ebiom.2016.11.034
16
PawlowskaMJarekDMilanowskiJSzewczyk-GolecK. Parasitic infections and carcinogenesis: molecular mechanisms, immune modulation, and emerging therapeutic strategies. Oncol Res. (2026) 34:8. doi: 10.32604/or.2025.071891
17
DingHWuSJinZZhengBHuYHeKet al. Anti-tumor effect of parasitic protozoans. Bioengineering (Basel). (2022) 9:395. doi: 10.3390/bioengineering9080395
18
ThamavitWBhamarapravatiNSahaphongSVajrastiraSAngsubhakornS. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res. (1978) 38:4634–9.
19
ThamavitWKongkanuntnRTiwawechDMooreMA. Level of Opisthorchis infestation and carcinogen dose-dependence of cholangiocarcinoma induction in Syrian golden hamsters. Virchows Arch B Cell Pathol incl Mol Pathol. (1987) 54:52–8. doi: 10.1007/bf02899196
20
ThamavitWMooreMAHiasaYItoN. Generation of high yields of Syrian hamster cholangiocellular carcinomas and hepatocellular nodules by combined nitrite and aminopyrine administration and Opisthorchis viverrini infection. Jpn J Cancer Res. (1988) 79:909–16. doi: 10.1111/j.1349-7006.1988.tb00054.x
21
MooreMAThamavitWHiasaYItoN. Early lesions induced by DHPN in Syrian golden hamsters: influence of concomitant Opisthorchis infestation, dehydroepiandrosterone or butylated hydroxyanisole administration. Carcinogenesis. (1988) 9:1185–9. doi: 10.1093/carcin/9.7.1185
22
MiyaharaKYokooNSakuraiHIgarashiISakataYYoshidaYet al. Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats. J Vet Med Sci. (1992) 54:221–8. doi: 10.1292/jvms.54.221
23
ThamavitWPairojkulCTiwawechDShiraiTItoN. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett. (1994) 78:121–5. doi: 10.1016/0304-3835(94)90040-x
24
ThamavitWTiwawechDMooreMAItoNShiraiT. Equivocal evidence of complete carcinogenicity after repeated infection of Syrian hamsters with Opisthorchis viverrini. Toxicol Pathol. (1996) 24:493–7. doi: 10.1177/019262339602400412
25
MooreMAThamavitWTiwawechDItoNTsudaH. Modulation of dihydroxy-di-n-propylnitrosamine-induced liver lesion development in Opisthorchis-infected Syrian hamsters by praziquantel treatment in association with butylated hydroxyanisole or dehydroepiandrosterone administration. Jpn J Cancer Res. (1998) 89:1113–7.
26
OliveiraECLeiteMSMirandaJAAndradeALGarciaSBLuquettiAOet al. Chronic Trypanosoma cruzi infection associated with low incidence of 1,2-dimethylhydrazine-induced colon cancer in rats. Carcinogenesis. (2001) 22:737–40. doi: 10.1093/carcin/22.5.737
27
BoonmarsTWuZBoonjaruspinyoSPinlaorSNaganoITakahashiYet al. Alterations of gene expression of RB pathway in Opisthorchis viverrini infection-induced cholangiocarcinoma. Parasitol Res. (2009) 105:1273–81. doi: 10.1007/s00436-009-1548-0
28
BotelhoMOliveiraPGomesJGartnerFLopesCda CostaJMet al. Tumourigenic effect of Schistosoma haematobium total antigen in mammalian cells. Int J Exp Pathol. (2009) 90:448–53. doi: 10.1111/j.1365-2613.2009.00650.x
29
BotelhoMFerreiraACOliveiraMJDominguesAMaChadoJCda CostaJM. Schistosoma haematobium total antigen induces increased proliferation, migration and invasion, and decreases apoptosis of normal epithelial cells. Int J Parasitol. (2009) 39:1083–91. doi: 10.1016/j.ijpara.2009.02.016
30
WuZBoonmarsTBoonjaraspinyoSNaganoIPinlaorSPuapairojAet al. Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection. Parasitol Res. (2011) 109:657–73. doi: 10.1007/s00436-011-2298-3
31
BotelhoMCOliveiraPALopesCCorreia da CostaJMMaChadoJC. Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium. Urol Oncol. (2011) 29:809–14. doi: 10.1016/j.urolonc.2009.09.017
32
ChanKHChandramathiSSureshKChuaKHKuppusamyUR. Effects of symptomatic and asymptomatic isolates of Blastocystis hominis on colorectal cancer cell line, HCT116. Parasitol Res. (2012) 110:2475–80. doi: 10.1007/s00436-011-2788-3
33
BenamrouzSGuyotKGazzolaSMourayAChassatTDelaireBet al. Cryptosporidium parvum infection in SCID mice infected with only one oocyst: qPCR assessment of parasite replication in tissues and development of digestive cancer. PloS One. (2012) 7:e51232. doi: 10.1371/journal.pone.0051232
34
BotelhoMCValeNGouveiaMJRinaldiGSantosJSantosLLet al. Tumour-like phenotypes in urothelial cells after exposure to antigens from eggs of Schistosoma haematobium: an oestrogen-DNA adducts mediated pathway? Int J Parasitol. (2013) 43:17–26. doi: 10.1016/j.ijpara.2012.10.023
35
El-TonsyMMHusseinHMHelal TelSTawfikRAKoriemKMHusseinHM. Schistosoma mansoni infection: is it a risk factor for development of hepatocellular carcinoma? Acta Trop. (2013) 128:542–7. doi: 10.1016/j.actatropica.2013.07.024
36
VasilevSIlicNGruden-MovsesijanAVasilijicSBosicMSofronic-MilosavljevicL. Necrosis and apoptosis in Trichinella spiralis-mediated tumour reduction. Cent Eur J Immunol. (2015) 40:42–53. doi: 10.5114/ceji.2015.50832
37
SmoutMJSotilloJLahaTPapatpremsiriARinaldiGPimentaRNet al. Carcinogenic parasite secretes growth factor that accelerates wound healing and potentially promotes neoplasia. PloS Pathog. (2015) 11:e1005209. doi: 10.1371/journal.ppat.1005209
38
ChaiyadetSSotilloJSmoutMCantacessiCJonesMKJohnsonMSet al. Carcinogenic liver fluke secretes extracellular vesicles that promote cholangiocytes to adopt a tumorigenic phenotype. J Infect Dis. (2015) 212:1636–45. doi: 10.1093/infdis/jiv291
39
LiaoCCSongEJChangTYLinWCLiuHSChenLRet al. Evaluation of cellular retinoic acid binding protein 2 gene expression through the retinoic acid pathway by co-incubation of Blastocystis ST-1 with HT29 cells in vitro. Parasitol Res. (2016) 115:1965–75. doi: 10.1007/s00436-016-4939-z
40
AgerbaekMOPereiraMAClausenTMPehrsonCOoHZSpliidCet al. Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration. Int J Cancer. (2017) 140:1597–608. doi: 10.1002/ijc.30575
41
ChaiyadetSSmoutMLahaTSripaBLoukasASotilloJ. Proteomic characterization of the internalization of Opisthorchis viverrini excretory/secretory products in human cells. Parasitol Int. (2017) 66:494–502. doi: 10.1016/j.parint.2016.02.001
42
HaugenBKarinshakSEMannVHPopratiloffALoukasABrindleyPJet al. Granulin secreted by the food-borne liver fluke Opisthorchis viverrini promotes angiogenesis in human endothelial cells. Front Med (Lausanne). (2018) 5:30. doi: 10.3389/fmed.2018.00030
43
StaffPNTD. Correction: Connexin 43 plays an important role in the transformation of cholangiocytes with Clonochis sinensis excretory-secretory protein and N-nitrosodimethylamine. PloS NeglTrop Dis. (2019) 13:e0007526. doi: 10.1371/journal.pntd.0007526
44
EissaMMIsmailCAEl-AzzouniMZGhazyAAHadiMA. Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer. Invest New Drugs. (2019) 37:47–56. doi: 10.1007/s10637-018-0609-6
45
LinYZhuSHuCWangJJiangPZhuLet al. Cross-species suppression of hepatoma cell growth and migration by a Schistosoma japonicum microRNA. Mol Ther Nucleic Acids. (2019) 18:400–12. doi: 10.1016/j.omtn.2019.09.006
46
Ruiz-ManzanoRAPalacios-ArreolaMIHernandez-CervantesRDel Rio-AraizaVHNava-CastroKEOstoa-SalomaPet al. Potential novel risk factor for breast cancer: Toxocara canis infection increases tumor size due to modulation of the tumor immune microenvironment. Front Oncol. (2020) 10:736. doi: 10.3389/fonc.2020.00736
47
WeglageJWoltersFHehrLLichtenbergerJWulzCHempelFet al. Schistosoma mansoni eggs induce Wnt/beta-catenin signaling and activate the protooncogene c-Jun in human and hamster colon. Sci Rep. (2020) 10:22373. doi: 10.1038/s41598-020-79450-4
48
HuCLiYPanDWangJZhuLLinYet al. A Schistosoma japonicum microRNA exerts antitumor effects through inhibition of both cell migration and angiogenesis by targeting PGAM1. Front Oncol. (2021) 11:652395. doi: 10.3389/fonc.2021.652395
49
SawantMBenamrouz-VannesteSMourayABouquetPGantoisNCreusyCet al. Persistent Cryptosporidium parvum infection leads to the development of the tumor microenvironment in an experimental mouse model: Results of a microarray approach. Microorganisms. (2021) 9:2569. doi: 10.3390/microorganisms9122569
50
ShahrivarFSadraeiJPirestaniMAhmadpourE. Enhancement of apoptosis in Caco-2, Hep-G2, and HT29 cancer cell lines following exposure to Toxoplasma gondii peptides. Drug Target Insights. (2024) 18:70–7. doi: 10.33393/dti.2024.3177
51
BelliniIScribanoDAmbrosiCChiovoloniCRondonSPronioAet al. Anisakis extracellular vesicles elicit immunomodulatory and potentially tumorigenic outcomes on human intestinal organoids. Parasit Vectors. (2024) 17:393. doi: 10.1186/s13071-024-06471-7
52
ReddyKBNabhaSMAtanaskovaN. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. (2003) 22:395–403. doi: 10.1023/a:1023781114568
53
ParkMHHongJT. Roles of NF-kappaB in cancer and inflammatory diseases and their therapeutic approaches. Cells. (2016) 5. doi: 10.3390/cells5020015
54
QuKWangZFanHLiJLiuJLiPet al. Correction to: MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis. (2022) 13:950. doi: 10.1038/s41419-022-05405-4
55
SripaBDeenonpoeRBrindleyPJ. Co-infections with liver fluke and Helicobacter species: a paradigm change in pathogenesis of opisthorchiasis and cholangiocarcinoma? Parasitol Int. (2017) 66:383–9. doi: 10.1016/j.parint.2016.11.016
56
Thorley-LawsonDDeitschKWDucaKATorgborC. The link between Plasmodium falciparum malaria and endemic Burkitt's lymphoma-new insight into a 50-year-old enigma. PloS Pathog. (2016) 12:e1005331. doi: 10.1371/journal.ppat.1005331
57
SanaBNedjoudGSihemKHadiaHAslamAAMughramMHAet al. N-nitrosodimethylamine as an emerging environmental contaminant: Sources, analytical advances, and ecotoxicological and human health risks. Int J Anal Chem. (2026) 2026:1536227. doi: 10.1155/ianc/1536227
58
MigasenaPReaunsuwanWChangbumrungS. Nitrates and nitrites in local Thai preserved protein foods. J Med Assoc Thai. (1980) 63:500–5.
59
ThamavitWMooreMAHiasaYItoN. Enhancement of DHPN induced hepatocellular, cholangiocellular and pancreatic carcinogenesis by Opisthorchis viverrini infestation in Syrian golden hamsters. Carcinogenesis. (1988) 9:1095–8. doi: 10.1093/carcin/9.6.1095
60
WagnerMNishikawaHKoyasuS. Reinventing type 2 immunity in cancer. Nature. (2025) 637:296–303. doi: 10.1038/s41586-024-08194-2
61
WagnerMKoyasuS. Cancer in disguise: a parasite within. EMBO J. (2026) 45:1051–9. doi: 10.1038/s44318-025-00691-y
62
ZaissDMWPearceEJArtisDMcKenzieANJKloseCSN. Cooperation of ILC2s and T(H)2 cells in the expulsion of intestinal helminth parasites. Nat Rev Immunol. (2024) 24:294–302. doi: 10.1038/s41577-023-00942-1
63
XuJDingLMeiJHuYKongXDaiSet al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. (2025) 10:268. doi: 10.1038/s41392-025-02325-5
64
WynnTAVannellaKM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. (2016) 44:450–62. doi: 10.1016/j.immuni.2016.02.015
65
GauseWCWynnTAAllenJE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. (2013) 13:607–14. doi: 10.1038/nri3476
66
DvorakHF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. (2015) 3:1–11. doi: 10.1158/2326-6066.cir-14-0209
67
LegrandFDrissVDelbekeMLoiseauSHermannEDombrowiczDet al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. (2010) 185:7443–51. doi: 10.4049/jimmunol.1000446
68
NielsenHJHansenUChristensenIJReimertCMBrunnerNMoesgaardF. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. (1999) 189:487–95. doi: 10.1002/(sici)1096-9896(199912)189:4<487::aid-path484>3.0.co;2-i
69
HuGWangSZhongKXuFHuangLChenWet al. Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis. BMC Cancer. (2020) 20:454. doi: 10.1186/s12885-020-06966-3
70
SimsonLEllyardJIDentLAMatthaeiKIRothenbergMEFosterPSet al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. (2007) 178:4222–9. doi: 10.4049/jimmunol.178.7.4222
71
TepperRIPattengalePKLederP. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. (1989) 57:503–12. doi: 10.1016/0092-8674(89)90925-2
72
FengBBaiZZhouXZhaoYXieYQHuangXet al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer. Nature. (2024) 634:712–20. doi: 10.1038/s41586-024-07962-4
73
AsghariANourmohammadiHMajidianiHShariatzadehSAAnvariDShamsiniaSet al. Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies. Environ Sci pollut Res Int. (2022) 29:32383–96. doi: 10.1007/s11356-021-17090-5
74
AslamARefaatBAlmaimaniRAObaidAAMujalliAFarrashWFet al. Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets. Discov Oncol. (2025) 16:637. doi: 10.1007/s12672-025-02452-z
75
ZhuJXuZChenXZhouSZhangWChiYet al. Parasitic antigens alter macrophage polarization during Schistosoma japonicum infection in mice. Parasit Vectors. (2014) 7:122. doi: 10.1186/1756-3305-7-122
76
WhittleHCBrownJMarshKGreenwoodBMSeidelinPTigheHet al. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature. (1984) 312:449–50. doi: 10.1038/312449a0
77
EveringTWeissLM. The immunology of parasite infections in immunocompromised hosts. Parasite Immunol. (2006) 28:549–65. doi: 10.1111/j.1365-3024.2006.00886.x
78
SeemaKKumarABoipaiMKumarMSharmaAK. Prevalence of intestinal parasites in HIV/AIDS-infected patients with correlation to CD4+ T-cell count at hospital in Eastern India. J Family Med Prim Care. (2023) 12:2884–7. doi: 10.4103/jfmpc.jfmpc_806_23
79
WondmagegnYMSetegnAGirmayGAbebeWDessieNAshagreAet al. Global prevalence of intestinal parasites in cancer patients: a systematic review and meta-analysis. BMC Infect Dis. (2025) 25:815. doi: 10.1186/s12879-025-11207-8
80
HataminejadMBasirpourBBaharlouMGholami KoohestanMZiaei HezarjaribiHRahimi EsboeiBet al. Global prevalence and correlation of intestinal parasitic infections in patients with colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. (2025) 25:584. doi: 10.1186/s12876-025-04144-y
Summary
Keywords
anticancer therapy, cancer biology, immune modulation, parasite-derived molecules, tumour microenvironment
Citation
Minshawi F, Alghanmi M, Alwafi H, Dustakir AM, Al Zoabi B, Khan S, Gattan HS, Alsaady IM, Altwaim SA, Oyelade T and Zawawi A (2026) The dual role of parasites and parasite-derived products in cancer biology: a systematic review of in vitro and in vivo evidence. Front. Oncol. 16:1894132. doi: 10.3389/fonc.2026.1894132
Received
28 May 2026
Revised
25 June 2026
Accepted
29 June 2026
Published
16 July 2026
Volume
16 - 2026
Edited by
Pritam Sadhukhan, National Institutes of Health (NIH), United States
Reviewed by
Marek Wagner, Łukasiewicz Research Network – PORT Polish Center for Technology Development, Poland
Marco Antonio Hernández-Luna, University of Guanajuato, Mexico
Updates
Copyright
© 2026 Minshawi, Alghanmi, Alwafi, Dustakir, Al Zoabi, Khan, Gattan, Alsaady, Altwaim, Oyelade and Zawawi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Faisal Minshawi, fominshawi@uqu.edu.sa
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.